TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Wound seroma formation
Endpoint domain: Adverse events/effects
Primary endpoint: Social Interaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State Organization
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: subsequent death after hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Cognitive and psychomotor measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of nurses passing knowledge and clinical skills tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in low back pain (LBP) treatment outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of END
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: better aperture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCΔUPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean percent reduction in total acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent reduction in inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean percent reduction in comedones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of neuromuscular electrical stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total plasma clozapine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial Fibrillation Rate (AFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QTcF Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of daily colic attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stone expulsion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in dryness symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in overall lens comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in tear meniscus height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of further surgical treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rates of amenorrhoea or brown discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PICF PGE2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine concentrations of genistein, daidzein, and equol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentrations of genistein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breast tissue homogenate concentrations of genistein, daidzein, and equol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IGFBP‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IGFBP‐3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: perioperative and postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: overall impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of complex plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: dynamic respiratory compliance values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: oxygenation index values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart rate variability reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TIMP‐1/MMP‐1 balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-18) of infliximab concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomarkers of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: important clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Orgasmic function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Balance improvement (BBS responders)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of non-failure patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean calculated creatinine clearance at 3 months posttransplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Biopsy-proven chronic allograft injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Graft failure
Endpoint domain: Mortality/survival
Primary endpoint: GSRS scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: motor improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster premotor and motor reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less variability in sustained muscular contraction task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Olfactory sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to have repeat unsedated colonoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean creatinine at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total dyspeptic symptoms scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Beneficial impact on vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentration of sC5b-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean concentration of polymorphonuclear-elastase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease in contractility and relaxation of uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Merle d'Aubigné score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable proximal fixation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: angiographic or clinical restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of type II diabetes mellitus (DM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: limb power improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPPB changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anesthesia satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: nursing care calls per day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction in plasma concentrations of AA and AA metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean UPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: postoperative complications rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vasovagal reactions
Endpoint domain: Adverse events/effects
Primary endpoint: self-perception of communication performance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: interaction factor
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: reaction factor
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of conversations about warnings and health effects
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Return to work
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost savings to health services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cocaine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma cocaine AUC (0‐480 min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 'Cocaine high'
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: biomarker response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach maximum drug concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum inhibition of the zero‐order synthesis rate of the factor causing fever (Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentration eliciting half of Emax (EC50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment satisfaction
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Vaccine efficacy against cervical intraepithelial neoplasia
Endpoint domain: Mortality/survival
Primary endpoint: Vaccine efficacy against vulvar and vaginal intraepithelial neoplasia or condylomata accuminata
Endpoint domain: Mortality/survival
Primary endpoint: Injection site adverse event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mean endothelial cell density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net sodium absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: composite of stroke, transient ischaemic attack, peripheral embolism, myocardial infarction, and cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: rates of poor outcome at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Mitral regurgitation severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion clinically cured
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion parasitological cured
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: multi-source feedback scores
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: ischemic stroke rates
Endpoint domain: Mortality/survival
Primary endpoint: intracerebral hemorrhage rates
Endpoint domain: Mortality/survival
Primary endpoint: any stroke relative risk
Endpoint domain: Mortality/survival
Primary endpoint: LF/HF ratio daytime
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Erythema and dry desquamation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: gains in narrative skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early literacy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal Incontinence Quality of Life domain scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Major infections
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality due to major infections
Endpoint domain: Mortality/survival
Primary endpoint: mean serum cortisol area under the curve (AUC0‐24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24‐h urinary cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: incidence of treatment‐emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: articular complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: cutaneous lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Treatment for disease progression
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean POP-ss scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean PFIQ-7 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Degree of arousal measured by BIS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in GER episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in esophageal acid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ACC score of zero
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in ACC score from baseline to day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACQA scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic care scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (bradycardia and hypertension)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum progesterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 17alpha-hydroxyprogesterone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Triceps skin fold thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mid-arm muscle circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean tHcy levels at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of clinically significant PCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Care Use (HCU)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quit attempts
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Successfully quitting smoking
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: No recall of being in the ICU
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Delusional memories 28 days after discharge
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of stomal complications
Endpoint domain: Adverse events/effects
Primary endpoint: hydroxybupropion/bupropion AUC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of hydroxybupropion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of hydrobupropion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Session attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Inhibition of ACTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Inhibition of cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24h-UFC/creatinine values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean modified HAMD17 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical functioning at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post operative nausea and vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Overall patient satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mitral annular plane systolic excursion (MAPSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early diastolic filling velocity (E-velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cognitive performance impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Memory performance impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth weight reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT values at left common femoral artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Contrast dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cement penetration into cancellous bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness in addressing childhood obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aromatase inhibitor-associated bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: percentage of subjects heartburn-free for 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percentage of heartburn-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: prevention of nocturnal heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: shoulder tip pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wound pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eczema Area Severity Index score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Haemoglobin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rHuEpo dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective exertion score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Patient-reported uncorrected vision score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Freedom from corrective wear
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of stasis-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in gastric emptying of solid meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: frequency of stone recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall low-trauma fractures
Endpoint domain: Mortality/survival
Primary endpoint: Improvements in linguistic and communicative abilities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standardized aphasia assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proxy rating of communicative effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient's pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgeon's discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized peak EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arterial oxygen partial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: arterial carbon dioxide partial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean peak inspiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean implant-related medialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total medialization of the COR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of cases with medialization ≥8 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lobene stain index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Societal cost
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: MVO ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spatial working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Planning accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Clearance of HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic stress symptoms level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acute stress disorder risk
Endpoint domain: Adverse events/effects